Background {#Sec1}
==========

Acute coronary syndrome (ACS) remains a leading cause of morbidity and mortality. In the USA alone, more than 1,000,000 suffer from ACS annually \[[@CR1]\]. The Global Registry of Acute Coronary Events (GRACE) study showed that the mortality rate of ACS patients after 1 year is approximately 15%, and the cumulative mortality rate after 5 years is as high as 20% \[[@CR2]\]. Consequently, early risk stratification is important to prevent and manage ACS \[[@CR3], [@CR4]\]. Insulin resistance (IR), the decreased insulin sensitivity of peripheral tissues characterized by defects in the uptake and oxidation of glucose, plays a critical role in the pathogenesis of diabetes as well as cardiovascular disease (CVD) \[[@CR5]\]. The molecular mechanisms include the roles of IR in vascular function, macrophage accumulation, atherosclerosis development and hypertension \[[@CR6], [@CR7]\]. Previous studies have noted that the hyperinsulinaemic-euglycaemic clamp is the gold standard diagnostic method for IR. However, the technique is difficult to implement in large epidemiological investigations because it is costly, time consuming and complex \[[@CR8]\]. Recently, the triglyceride--glucose index (TyG index), the product of fasting plasma glucose (FPG) and triglycerides (TGs), has been used in clinical practice as a simple and reliable surrogate marker of IR \[[@CR9], [@CR10]\]. In addition, the TyG index has been shown to be well correlated with the homeostasis model assessment of insulin resistance (HOMA-IR) and hyperinsulinaemic-euglycaemic clamp \[[@CR11]--[@CR13]\]. Zhang et al. showed that the cumulative risk of incident type 2 diabetes mellitus (DM) increased with the TyG index \[[@CR14]\]. In addition, previous studies have shown that the TyG index is associated with coronary artery calcification, carotid atherosclerosis, symptomatic coronary artery disease and a high risk of CVD \[[@CR15]--[@CR18]\]. Moreover, Sanchez et al. showed associations of the highest TyG index values with the incidence of stroke and hypertension and that the TyG index may predict the development of cardiovascular events \[[@CR19]--[@CR21]\]. To the best of our knowledge, the relationship between TyG index levels and clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) has not been fully evaluated. The purpose of this study was to explore the predictive value of TyG index levels on the clinical outcomes of STEMI patients after PCI and to provide ideas for improving STEMI risk stratification.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

This study is a retrospective observational cohort study. From January 2012 to March 2018, consecutive patients with STEMI admitted to Zhongda Hospital (Nanjing, People's Republic of China) were enrolled. The inclusion criteria were as follows: (1) 18 ≤ age ≤ 80 years old and (2) diagnosis of STEMI based on the Guidelines for the Diagnosis and Treatment of Acute ST-segment Elevation Myocardial Infarction in 2010 (China) \[[@CR22]\] and treatment with PCI. The exclusion criteria were as follows: a history of major surgery, trauma or bleeding over the past 3 months; malignant tumour; serious injury of liver or kidney; contraindications to anticoagulant and antiplatelet therapy; and incomplete clinical data and coronary angiography.

Grouping {#Sec4}
--------

The patients were divided into 4 quartiles according to TyG index levels, Q1 (n = 273, TyG index ≤ 8.691), Q2 (n = 273, 8.692 ≤ TyG index ≤ 9.097), Q3 (n = 273, 9.098 ≤ TyG index ≤ 9.607), and Q4 (n = 273, TyG index ≥ 9.608).

Laboratory investigations {#Sec5}
-------------------------

Blood samples were obtained from each patient from the cubital vein after an overnight fast ≥ 12 h. Concentrations of FPG were measured by the enzymatic hexokinase method. TGs, total cholesterol (TC), high-density lipoprotein--cholesterol (HDL-C), and low-density lipoprotein--cholesterol (LDL-C) were measured using an automatic biochemistry analyser (Hitachi 7150, Japan) in an enzymatic assay. The TyG index was calculated using the following formula: ln \[fasting TGs (mg/dL) × FPG (mg/dL)/2\] \[[@CR23]\].

Percutaneous coronary intervention {#Sec6}
----------------------------------

PCI includes balloon dilation and/or stent implantation for infarct-related vessels and was performed by experienced operators according to standard techniques. All patients were given aspirin (300 mg), ticagrelor (180 mg) or clopidogrel (300 mg) before surgery, and aspirin (100 mg, QD), ticagrelor (90 mg, BID) or clopidogrel (75 mg, QD) were administered after surgery. Statins, nitrates, beta blockers, and angiotensin-converting enzyme inhibitors were commonly used in all patients without contraindications.

Endpoints and definitions {#Sec7}
-------------------------

The endpoints were major adverse cardiac and cerebrovascular events (MACCEs) during the follow-up period (30 days, 6 months and 1 year after PCI). The MACCEs included all-cause death, target vessel revascularization, myocardial infarction during follow-up, unstable angina pectoris requiring hospitalization, heart failure, stroke or transient cerebral ischaemia.

Hypertension was defined as a self-reported physician-diagnosed condition, currently use of antihypertensive treatment, and/or systolic blood pressure (SBP) ≥ 140 mm Hg and/or diastolic blood pressure (DBP) ≥ 90 mmHg \[[@CR24]\]. Diabetes was defined according to one of the following criteria: (1) self-reported diabetes that was previously diagnosed by a physician or the use of glucose-lowering drugs before hospitalization; (2) any one of the characteristic symptoms of DM such as thirst, polyuria, polyphagia, and weight loss with any blood glucose estimation exceeding 11.1 mmol/L; (3) a fasting blood glucose level in excess of 7.0 mmol/L after an overnight fast of 8 h; and (4) a 2-h blood glucose estimation exceeding 11.1 mmol/L after a 75 g glucose load via an oral glucose tolerance test after an overnight fast of 8 h \[[@CR25]\].

Each patient's baseline clinical data, including sex, age, height, weight, heart rate, SBP, DBP, and Killip class, as well as previous and personal histories, including hypertension, diabetes, atrial fibrillation, anaemia, previous myocardial infarction (MI) and smoking history, were recorded. Haematological examination indexes, including white blood cells, neutrophil-to-platelet ratio, albumin, measured HbA1c, high-sensitivity C-reactive protein (hs-CRP), uric acid, estimated glomerular filtration rate (eGFR), cardiac troponin I, N-terminal proB-type natriuretic peptide (NT-proBNP), echocardiography parameters, medications, and coronary angiography data were recorded. Killip classification was a useful tool for risk stratification. Killip class I was defined by the absence of signs of pulmonary congestion or systemic hypoperfusion. Killip class II was defined by the presence of rales in the lower half of the lung fields or by the presence of gallop heart sounds; Killip class III was defined by the presence of rales in the upper half of the lung fields; and Killip class IV was characterized by cardiogenic shock (significant hypotension: SBP \< 90 mm Hg or requiring inotropes) \[[@CR26]\]. Body mass index (BMI) was calculated as the body mass divided by the square of the body height and expressed in units of kg/m^2^. Blood pressure (BP) was measured by experienced physicians using an automated BP monitor (HEM-7080IC; Omron Healthcare, Lake Forest, IL, USA). Patients were seated for at least 10 min in a quiet environment with their feet on the floor and their arm supported at heart level. The average of 3 consecutive BP measurements taken at 2-min intervals on the same arm was recorded for the study. The Gensini score of each patient was calculated according to the results of coronary angiography. Follow-up data were obtained from hospital records or via interviews (in person or by telephone) of patients and their families conducted by at least two cardiologists.

Statistical analysis {#Sec8}
--------------------

Analyses were performed using SPSS software, version 19.0 (SPSS, Inc., Chicago, IL, USA). Continuous variables are expressed as the mean ± SD or median (inter-quartile range). Categorical variables are reported in frequencies with percentages. Univariate and multivariate logistic regression analyses were used to identify MACCE predictors. Variables with univariate P values \< 0.10 were selected for multivariate analysis and are expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Survival was graphically represented using Kaplan--Meier curves. Differences in survival rates were compared using the log-rank test. The area under the receiver operating characteristic (ROC) curves (AUCs) was used to indicate the predictive value of the TyG index for MACCEs. All tests were 2-tailed, and statistical significance was defined as a P-value \< 0.05.

Results {#Sec9}
=======

Patient characteristics {#Sec10}
-----------------------

Briefly, 1178 individuals fulfilled the inclusion criteria. A group of 32 patients had missing laboratory values, and 54 did not complete the follow-up. These restrictions left 1092 participants available for the final baseline analysis. The study population had an average age of 62.4 ± 12.5 years and an average BMI of 25.2 ± 2.2 kg/m^2^; 864 (79.1%) were male. A total of 678 patients (62.1%) had a history of hypertension, and 270 patients (24.7%) had a history of DM. All patients were subdivided into 4 groups according to TyG index levels. The baseline characteristics of the 4 groups are shown in Table [1](#Tab1){ref-type="table"}. There were statistically significant differences (P \< 0.05) among the four groups in terms of age, BMI, SBP, DBP, heart rate, hypertension, DM, platelets, albumin, FPG, measured HbA1c, TGs, TC, HDL-C, LDL-C, uric acid, three-vessel disease, and Gensini score, and no statistically significant differences were found in the other indicators. The TyG index was positively correlated with BMI, SBP, DBP, heart rate, platelets, albumin, FPG, measured HbA1c, TGs, TC, HDL-C, LDL-C, uric acid, and Gensini score, while it was negatively related to age. Patients with a high TyG index had a higher incidence of hypertension (P \< 0.001), DM (P \< 0.001) and three-vessel disease (P \< 0.001).Table 1Baseline characteristics of 4 groupsVariableQ1 (n = 273)Q2 (n = 273)Q3 (n = 273)Q4 (n = 273)P valueTyG index8.373 ± 0.2588.905 ± 0.1229.345 ± 0.14510.076 ± 0.483\< 0.001Age, years65.2 ± 13.263.5 ± 10.861.2 ± 11.657.6 ± 12.4\< 0.001Male219 (80.2)220 (80.6)222 (81.3)213 (78.0)0.546BMI, kg/m225.2 (24.7--25.5)25.5 (25.1--25.8)26.0 (25.6--26.2)26.5 (26.0--26.9)0.012SBP, mmHg124.9 ± 22.1128.7 ± 21.9129.9 ± 20.8138.3 ± 22.6\< 0.001DBP, mmHg75.2 ± 14.176.6 ± 13.477.1 ± 14.384.7 ± 16.8\< 0.001Heart rate, bpm77.7 ± 14.579.7 ± 13.179.0 ± 12.782.2 ± 16.30.019Killip class \> 182 (30.3)85 (31.1)91 (33.3)89 (32.6)0.523Smoker114 (41.8)120 (44.0)123 (45.1)126 (46.2)0.886Hypertension138 (50.5)162 (60.0)177 (64.8)201 (73.6)\< 0.001Diabetes mellitus21 (7.7)45 (16.5)81 (29.7)123 (45.1)\< 0.001Anemia33 (12.1)26 (9.5)30 (11.0)35 (12.8)0.322Previous AMI6 (2.2)6 (2.2)7 (2.6)8 (2.9)0.489Atrial fibrillation16 (5.8)13 (4.8)17 (6.2)15 (5.5)0.652Biochemical indicators NT-proBNP, pg/mL (IQR)525.5 (31.0--2193.2)534.4 (53.5--2293.7)527.6 (34.9--2401.4)546 (71.2--2603.2)0.179 Cardiac troponin I, ng/ml (IQR)12.2 (3.01--22.7)11.6 (2.7--23.1)13.1 (2.3--23.9)12.7 (2.6--24.2)0.762 hs-CRP, mg/L (IQR)7.9 (5.5--10.4)7.3 (4.4--11.1)6.9 (3.9--9.7)7.3 (3.4--10.7)0.652 White blood cells, 10^9^/L9.9 ± 3.910.0 ± 3.910.0 ± 3.210.2 ± 3.20.826 Neutrophil ratio75.5 ± 10.376.2 ± 11.475.2 ± 13.675.9 ± 12.90.775 Platelet, 10^9^/L195.0 ± 56.1201.8 ± 60.5228.8 ± 63.0223.8 ± 53.9\< 0.001 Albumin, g/L36.1 ± 4.837.3 ± 4.137.6 ± 4.538.2 ± 5.20.022 FPG, mmol/L6.6 ± 1.97.1 ± 1.88.1 ± 2.411.7 ± 6.0\< 0.001 Measured HbA1c,  % (IQR)6.5 (6.2--6.8)7.1 (6.9--7.4)7.6 (7.5--7.8)8.0 (7.9--8.2)\< 0.001 TC, mmol/L4.0 ± 0.94.3 ± 1.04.8 ± 1.25.2 ± 1.3\< 0.001 Triglycerides, mmol/L0.9 ± 0.31.4 ± 0.31.9 ± 0.63.6 ± 2.6\< 0.001 HDL-C, mmol/L1.0 ± 0.31.1 ± 0.21.2 ± 0.31.2 ± 0.3\< 0.001 LDL-C, mmol/L2.4 ± 0.72.7 ± 0.83.0 ± 1.03.1 ± 0.8\< 0.001 Uric acid, umol/L319.5 ± 102.6325.5 ± 87.3342.2 ± 109.3347.4 ± 100.60.019 eGFR, mL/min87.0 ± 32.885.4 ± 42.086.9 ± 34.389.5 ± 39.10.423Coronary angiography GPIIb/IIIa antagonists91 (33.3)89 (32.6)86 (31.8)92 (33.7)0.644 Anticoagulation25 (9.2)27 (9.9)22 (8.1)24 (8.8)0.546 Lesion vessels3.2 ± 1.63.2 ± 1.53.0 ± 1.83.1 ± 1.30.743 Three-vessel disease105 (38.5)138 (50.5)150 (54.9)168 (61.5)\< 0.001 Number of stents1.03 ± 0.541.02 ± 0.471.02 ± 0.451.11 ± 0.500.114 Gensini score, (IQR)61.6 (49.3--75.7)65.4 (54.1--72.6)71.6 (60.9--79.3)78.3 (63.1--83.9)0.049Echocardiography LVEF0.55 ± 0.120.54 ± 0.100.56 ± 0.100.55 ± 0.120.335Medications use at discharge Aspirin255 (93.4)264 (96.7)264 (96.7)267 (97.8)0.059 Clopidogrel/Ticagrelor267 (97.8)270 (98.9)267 (97.8)273 (100)0.082 Statin261 (95.6)265 (97.1)267 (97.8)260 (95.2)0.321 Beta blockers215 (78.8)228 (83.5)210 (76.4)223 (81.1)0.247 ACEI/ARB168 (61.1)180 (65.5)171 (62.2)183 (66.5)0.205Data are presented as the IQR, mean ± SD or n (%)*BMI* body mass index, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *AMI* acute myocardial infarction, *IQR* interquartile range, *hs-CRP* hypersensitive C-reactive protein, *FPG* fasting plasma glucose, *TC* total cholesterol, *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *SCr* Serum creatinine concentration, *eGFR* estimated glomerular filtration rate, *LVEF* left ventricular ejection fraction

Risk factors for MACCEs {#Sec11}
-----------------------

The baseline characteristics of the MACCE and MACCE-free groups are shown in Table [2](#Tab2){ref-type="table"}. The prevalence of Killip class \> 1, smoking history, hypertension, DM, anaemia, lesion vessels, number of stents and three-vessel disease of the MACCE group were higher than that of the MACCE-free group (all P \< 0.05). There were statistically significant differences (P \< 0.05) between the MACCE and MACCE-free groups in terms of age, DBP, white blood cells, platelets, albumin, FPG, measured HbA1c, uric acid, eGFR and left ventricular ejection fraction (LVEF).Table 2Baseline characteristics of the MACCE and MACCE-free groupsVariableMACCE group (n = 375)MACCE-free group (n = 717)P valueAge, years64.5 ± 12.561.3 ± 12.4\< 0.001Male300 (80.0)564 (78.7)0.638BMI, kg/m^2^25.3 ± 2.125.1 ± 2.40.382SBP, mmHg128.7 ± 18.9128.8 ± 22.70.939DBP, mmHg76.1 ± 13.978.0 ± 14.10.028Heart rate, bpm79.5 ± 15.479.7 ± 14.50.905Killip class \> 1142 (37.9)210 (29.3)\< 0.001Smoker199 (53.1)317 (44.2)0.012Hypertension261 (69.6)417 (58.2)\< 0.001Diabetes mellitus117 (31.2)153 (21.3)\< 0.001Anemia67 (17.9)74 (10.3)0.023Previous AMI9 (2.4)15 (2.1)0.447Atrial fibrillation15 (4.0)33 (4.6)0.385Biochemical indicators NT-proBNP, pg/mL (IQR)525.5 (31.0--2193.2)546.8 (71.2--2603.2)0.179 Cardiac troponin I, ng/ml13.1 (3.18--23.5)12.7 (2.8--23.2)0.480 hs-CRP, mg/L (IQR)7.6 (4.6--9.8)7.1 (3.2--10.1)0.152 White blood cells, 10^9^/L10.4 ± 3.69.9 ± 3.40.046 Neutrophil ratio75.6 ± 12.875.8 ± 11.80.680 Platelet, 10^9^/L217.2 ± 68.6208.4 ± 56.80.024 Albumin, g/L36.4 ± 5.737.1 ± 4.50.021 FPG, mmol/L9.0 ± 4.28.3 ± 4.40.008 Measured HbA1c, %7.8 ± 1.37.3 ± 1.40.010 TC, mmol/L4.6 ± 1.44.6 ± 1.10.781 Triglycerides, mmol/L1.9 ± 1.61.9 ± 1.40.502 HDL-C, mmol/L1.1 ± 0.31.1 ± 0.20.417 LDL-C, mmol/L2.8 ± 0.92.9 ± 0.80.412 Uric acid, umol/L342.3 ± 112.2321.6 ± 100.30.002 eGFR, mL/min79.4 ± 36.786.5 ± 37.40.008Coronary angiography GPIIb/IIIa antagonists121 (33.8)237 (33.0)0.515 Anticoagulation33 (8.8)65 (9.1)0.482 Lesion vessels3.3 ± 1.52.9 ± 1.5\< 0.001 Three-vessel disease213 (56.8)348 (48.5)\< 0.001 Number of stents1.0 ± 0.491.12 ± 0.50\< 0.001 Gensini score, (IQR)73.1 (45.3--94.8)67.0 (36.3--89.8)0.035Echocardiography LVEF0.53 ± 0.120.55 ± 0.110.037Medications use at discharge Aspirin357 (95.2)693 (96.7)0.154 Clopidogrel/Ticagrelor369 (98.4)708 (98.7)0.414 Statin366 (97.6)687 (95.8)0.088 Beta blockers301 (80.3)576 (80.3)0.477 ACEI/ARB240 (64.0)462 (64.4)0.469Data are presented as the IQR, mean ± SD or n (%)*BMI* body mass index, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *AMI* acute myocardial infarction, *IQR* interquartile range, *hs-CRP* hypersensitive C-reactive protein, *FPG* fasting plasma glucose, *TC* total cholesterol, *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *SCr* serum creatinine concentration, *eGFR* estimated glomerular filtration rate, *LVEF* left ventricular ejection fraction, *ACEI* angiotensin converting enzyme inhibitor, *ARB* angiotensin receptor blocker

Univariate and multivariate analyses and predictors for MACCEs within 1 year after PCI are presented in Table [3](#Tab3){ref-type="table"}. Univariate logistic regression showed that TyG index, age, Killip class \> 1, smoking history, hypertension, DM, anaemia, three-vessel disease, DBP, white blood cells, platelets, albumin, measured HbA1c, uric acid, eGFR, lesion vessels, number of stents and LVEF were risk factors for MACCEs in STEMI patients after PCI (all P \< 0.05). Co-linearity analysis of MACCEs predictors and TyG index are presented in Table [4](#Tab4){ref-type="table"}. Co-linearity analysis showed that hypertension, diabetes, HbA1c, FPG and TyG index had high co-linearity. Therefore, hypertension, diabetes, HbA1c and FPG were not included in the multivariate model. After adjusting for age and other potential confounding factors, multivariate logistic regression showed that the TyG index, Killip class \> 1, anaemia, albumin, uric acid, number of stents and LVEF were independent predictors of MACCEs in STEMI patients after PCI (all P \< 0.05).Table 3Univariate and multivariate analysis and predictors of MACCEs within 1 year after PCIVariableUnivariate analysisMultivariate analysisOR95% CIP valueOR95% CIP valueTyG index grouping Q111 Q21.0960.778--1.5450.6001.1170.668--1.8430.587 Q31.5421.083--2.1940.0161.3560.852--2.1600.199 Q41.8091.263--2.5900.0011.5291.001--2.0610.003Age, years1.0211.011--1.032\< 0.0011.0110.992--1.0310.233Male0.9220.676--1.2560.605BMI, kg/m^2^1.0050.950--1.0430.460SBP, mmHg1.0010.994--1.0060.839DBP, mmHg0.9900.981--0.9990.0290.9930.982--1.0050.258Heart rate, bpm0.9990.991--1.0080.905Killip class \> 12.1881.667--2.874\< 0.0011.7221.185--2.4710.002Smoker1.3471.047--1.7330.0201.1910.858--1.6530.297Hypertension1.6311.250--2.127\< 0.001Diabetes mellitus1.6721.261--2.216\< 0.001Anemia1.3510.940--1.941\< 0.0011.2820.995--1.5630.024Previous AMI1.1510.499--2.6550.742Atrial fibrillation0.8640.463--1.6110.645Biochemical indicators NT-proBNP, pg/mL (IQR)1.0570.909--1.1580.770 Cardiac troponin I, ng/ml1.0180.830--1.2570.571 hs-CRP, mg/L (IQR)1.0260.975--1.0740.302 White blood cells, 10^9^/L1.0371.001--1.0750.0471.0380.988--1.0910.141 Neutrophil ratio0.9980.988--1.0080.680 Platelet, 10^9^/L1.0021.000--1.0040.0251.0020.999--1.0040.285 Albumin, g/L0.9710.947--0.9960.0230.9630.928--1.0000.050 Measured HbA1c,  %1.1731.042--1.3210.005 FPG, mmol/L1.0401.010--1.0720.009 TC, mmol/L1.0150.916--1.1240.781 Triglycerides, mmol/L1.0210.909--1.1310.503 HDL-C, mmol/L0.8130.494--1.3390.813 LDL-C, mmol/L0.9380.806--1.0920.412 Uric acid, umol/L1.0021.001--1.0030.0021.0021.000--1.0040.013 eGFR, mL/min0.9950.991--0.9990.0090.9990.993--1.0050.751Coronary angiography GPIIb/IIIa antagonists0.9100.703--1.1760.470 Anticoagulation1.4060.773--2.5570.264 Lesion vessels1.1631.071--1.263\< 0.0011.0920.960--1.2430.180 Three-vessel disease1.3941.084--1.7930.0101.2440.830--1.8650.289 Number of stents1.5751.220--2.032\< 0.0011.7091.229--2.3750.001 Gensini score1.0081.002--1.0170.0221.0020.993--1.0100.366 LVEF0.3030.099--0.9310.0370.1210.029--0.0570.004Medications use at discharge Aspirin0.6870.368--1.2820.238 Clopidogrel/ticagrelor0.7820.276--2.2130.643 Statin1.7760.834--3.7810.136 Beta blockers0.9790.716--1.3390.895 ACEI/ARB1.2080.917--1.5900.179Co-linearity analysis showed that hypertension, diabetes, HbA1c, FPG and TyG index had high co-linearity. Therefore, hypertension, diabetes, HbA1c and FPG weren't included in multivariate model*BMI* body mass index, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *AMI* acute myocardial infarction, *IQR* interquartile range, *hs-CRP* hypersensitive C-reactive protein, *TC* total cholesterol, *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *SCr* Serum creatinine concentration, *eGFR* estimated glomerular filtration rate, *LVEF* left ventricular ejection fraction, *ACEI* angiotensin converting enzyme inhibitor, *ARB* angiotensin receptor blocker Table 4Co-linearity analysis of MACCEs predictors and TyG indexUnstandardized coefficientsStandardized coefficientstSig.Collinearity statisticsBStd. errorBetaToleranceVIF(Constant)6.6830.35618.7580.000Age, years− 0.0060.002− 0.100− 2.4060.0160.4242.361DBP, mmHg0.0050.0010.0983.2310.0010.8011.248Killip class \> 1− 0.0800.056− 0.044− 1.4150.1570.7541.325Smoker0.0940.0430.0662.1840.0290.8031.245Hypertension0.0660.0630.2061.0500.2980.09710.331Diabetes mellitus0.2870.3710.2070.7720.4440.05219.393Anemia− 0.0410.066− 0.018− 0.6170.5380.8241.214White blood cells− 0.0120.006− 0.061− 1.9310.0540.7411.349Platelet0.0010.0030.1113.7000.0000.8611.225Albumin0.0210.0050.1374.4610.0000.8611.225Measured HbA1c− 0.0530.024− 0.447− 2.1670.0350.08711.464FPG0.5450.0981.0835.5760.0000.09810.171Uric acid0.0310.0150.0652.2450.0250.8641.157eGFR0.0020.0010.1162.9700.0030.4752.106Lesion vessels− 0.0150.017− 0.033− 0.9000.3680.5511.814three-vessel disease0.1180.0520.0822.2830.0230.5601.787Number of stents0.0870.0060.4824.7210.0020.6821.160Gensini score0.0740.0300.2932.4560.0180.2603.848LVEF0.5080.1860.0802.7330.0060.8621.160Dependent variable: TyG index

The ROC curves of the TyG index as a marker to predict MACCEs in STEMI patients after PCI are illustrated in Fig. [1](#Fig1){ref-type="fig"}. The AUC of the TyG index for predicting the occurrence of MACCEs in STEMI patients after PCI was 0.685 (95% CI 0.610--0.761; P = 0.001). The AUCs of the TyG index for predicting the occurrence of MACCEs after adjusting for sex and DM are shown in Table [5](#Tab5){ref-type="table"}. The AUCs of FPG, TGs and the TyG index for predicting the occurrence of MACCEs are shown in Table [6](#Tab6){ref-type="table"}.Fig. 1The receiver operating characteristic (ROC) curves of the triglyceride-glucose index as a marker to predict MACCEs in STEMI patients after PCI. The area under ROC curves (AUCs) of the triglyceride-glucose index for predicting the occurrence of MACCEs in STEMI patients within 1 year after PCI was 0.685 (95% CI 0.610--0.761; P = 0.001) Table 5AUCs of the TyG index predicting the occurrence of MACCEs after adjusting for sex and DMVariablesTyG indexMaleFemaleDMNon-DMAUC (95% CI)0.705 (0.618--0.796)0.654 (0.588--0.679)0.699 (0.613--0.785)0.678 (0.611--0.746)P value0.0080.0190.0010.015*DM* diabetes mellitus, *TyG index* the triglyceride--glucose index Table 6AUCs of FPG, TGs and TyG index predicting the occurrence of MACCEsVariablesAUC (95% CI)P valueFPG0.642 (0.546--0.738)0.011TG0.549 (0.483--0.614)0.217TyG index0.685 (0.610--0.761)0.001*FPG* fasting plasma glucose, *TG* triglycerides, *TyG index* the triglyceride--glucose index

The Kaplan--Meier curve showing the follow-up without a MACCE (MACCE-free) survival curve of each TyG index group is illustrated in Fig. [2](#Fig2){ref-type="fig"}. The cumulative probability of overall survival of the 4 groups at the 1-year follow-up is illustrated in Fig. [3](#Fig3){ref-type="fig"}. The MACCE-free survival curve of 4 groups of male patients is illustrated in Fig. [4](#Fig4){ref-type="fig"}, and the MACCE-free survival curve of 4 groups of female patients is illustrated in Fig. [5](#Fig5){ref-type="fig"}. The incidence of MACCEs and all-cause mortality within 30 days, 6 months and 1 year after PCI were higher among STEMI patients with TyG index levels in the highest quartile (Q4).Fig. 2The follow-up without a MACCE (MACCE-free) survival curve of 4 groups. The incidence of MACCEs within 30 days, 6 months and 1 year after PCI was higher among STEMI patients with TyG index levels in the highest quartile (Q4) Fig. 3Cumulative probability of overall survival of 4 groups during the 1-year follow-up. The incidence of all-cause mortality within 30 days, 6 months and 1 year after PCI was higher among STEMI patients with TyG index levels in the highest quartile (Q4) Fig. 4The follow-up without a MACCE (MACCE-free) survival curve of 4 groups of male patients. The incidence of MACCEs within 30 days, 6 months and 1 year after PCI was higher among male STEMI patients with TyG index levels in the highest quartile (Q4) Fig. 5The follow-up without a MACCE (MACCE-free) survival curve of 4 groups of female patients. The incidence of MACCEs within 30 days, 6 months and 1 year after PCI was higher among female STEMI patients with TyG index levels in the highest quartile (Q4)

Discussion {#Sec12}
==========

In this study, we investigated the prognostic role of the TyG index in STEMI patients undergoing PCI. This study, for the first time, demonstrated that the incidence of MACCEs and all-cause mortality within 30 days, 6 months and 1 year after PCI was higher among STEMI patients with TyG index levels in the highest quartile. After adjusting for the confounding factors, the TyG index was significantly associated with an increased risk of MACCEs in STEMI patients within 1 year after PCI, with a value of 1.529 (95% CI 1.001--2.061; P = 0.003) for those in the highest quartile. In addition, the ROC curve showed that the TyG index had a high predictive value for MACCEs in STEMI patients.

IR is defined as a clinical or experimental condition in which insulin exerts a lower biological effect than expected. IR can induce an imbalance in glucose metabolism that generates chronic hyperglycaemia, which in turn triggers oxidative stress and causes an inflammatory response that leads to cell damage. Moreover, IR can also alter systemic lipid metabolism, which then leads to the development of dyslipidaemia. Overall, IR contributes to the development of CVD primarily via two independent pathways: (1) atheroma plaque formation and (2) ventricular hypertrophy and diastolic abnormality \[[@CR27]\]. Interestingly, a strong correlation between IR and the risk of developing CVD has been established \[[@CR28]\]. The Bruneck study revealed that IR is associated with subsequent symptomatic CVD independent of traditional risk factors in the general population \[[@CR7]\]. Eddy et al. showed that IR is likely the most significant single cause of coronary artery disease \[[@CR29]\].

The TyG index is a composite indicator composed of TGs and FBG, has been demonstrated to be a good marker of IR and has a high sensitivity and specificity for identifying metabolic syndrome \[[@CR30]\]. Several studies have documented the TyG index as a surrogate for identifying IR \[[@CR11], [@CR12], [@CR31], [@CR32]\]. In addition, it has been reported that the TyG index might be useful for the early identification of apparently healthy individuals at high risk of developing cardiovascular events \[[@CR18]\]. The findings of Won et al. showed that the TyG index is significantly associated with the presence and severity of CAD and severe coronary calcification \[[@CR33]\]. Alessandra et al. showed that the TyG index was positively associated with a higher prevalence of symptomatic CAD and could be used as a marker of atherosclerosis \[[@CR17]\]. Lee et al. showed that a higher TyG index is associated with an increased risk of coronary artery stenosis in asymptomatic subjects with type 2 diabetes, particularly when they have risk factors for cardiovascular disease \[[@CR34]\]. The findings of Jin et al. showed that the TyG index was positively associated with future cardiovascular events, suggesting that the TyG index may be a useful marker for predicting clinical outcomes in patients with CAD and that the TyG index might have better prognostic value than haemoglobin glycation indexes (HGIs) in diabetes patients with new-onset, stable CAD \[[@CR35], [@CR36]\]. A recent study showed that the TyG index might be an independent predictor of coronary artery disease severity and cardiovascular outcomes in non-ST-segment elevation acute coronary syndrome \[[@CR37]\]. However, no data are currently available regarding the effects of the TyG index on clinical outcomes in STEMI patients undergoing PCI. Our study indicated an association between higher TyG index levels and an increased risk of MACCEs for the first time, and the TyG index might be a valid predictor of clinical outcomes in STEMI patients undergoing PCI. Xue et al. found substantial similarities in the inflammatory profiles associated with diabetes and CVD \[[@CR29]\]. The mechanisms underlying the close connection between the TyG index and CVD may be attributed to systemic inflammation, oxidative stress, endothelial dysfunction, and vascular remodelling mediated by IR \[[@CR6], [@CR30], [@CR31], [@CR38]\]. In addition, Zhang et al. found that the risk of incident diabetes was increased with increasing TyG index among rural Chinese people, and the index might be an important indicator to identify people at high risk of diabetes \[[@CR39]\]. Moreover, there were also studies showing that the TyG index may help select people at early risk of future stroke and hypertension without other strong independent risk factors \[[@CR19], [@CR21]\]. However, more efforts need to be made to clarify the exact mechanisms of the association between the TyG index and CVD, stroke, hypertension and metabolic disorders and to provide ideas for improving risk stratification.

Study limitations {#Sec13}
=================

The following limitations of the present study should be addressed. First, the findings are restricted to a selected group of Chinese patients from one centre, and the follow-up time might not be long enough. Second, the use of hypoglycaemic treatment was not recorded, and the changes in the TyG index during the follow-up period were not measured or analysed. Third, other confounding factors, such as cardiorespiratory fitness, nutritional data and exercise habits, were not included in the model. A larger sample size, longer follow-up time, and multi-centre trials are necessary to confirm our findings.

Conclusion {#Sec14}
==========

In conclusion, the current study first demonstrated that higher TyG index values represent a strong independent predictor of an increased risk of MACCEs in STEMI patients within 1 year after PCI. In addition, Killip class \> 1, anaemia, albumin, uric acid, number of stents and LVEF were independent predictors of MACCEs in STEMI patients within 1 year after PCI. Based on these strong results, the TyG index might be a simple, easy-to-use, reliable parameter to predict the prognosis of STEMI patients and to provide ideas for improving STEMI risk stratification.
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